Actogenix N.v.

Actogenix N.V. is a clinical-stage biotechnology company focused on the development of novel therapeutics for the treatment of gastrointestinal disorders and cancer. The company's proprietary platform technology, Lactobacillus Biofactories, enables the oral delivery of therapeutic proteins to target specific disease areas. Actogenix is dedicated to bringing innovative and effective treatments to patients in need.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

9 Patents

#11 in Zwijnaarde

#280 in Belgium

Zwijnaarde, Belgium

Actogenix N.v.

Forward Citations = 44

9 inventors:

Lothar Steidler (4 out of 28 patents)

Pieter Rottiers (4 out of 15 patents)

Veerle Snoeck (3 out of 24 patents)

4. Klaas Vandenbroucke (2 out of 12 patents)

5. Sabine Neirynck (1 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Actogenix N.v.. Retrieved from https://idiyas.com/company/actogenix-n-v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

6 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]